Janux Doses First Patient in JANX013 Combination Study

The Tip Desk · November 11, 2026 · 2 min read

The clinical-stage immunotherapy company posted a $21.6 million net loss for the quarter ended September 30, 2026, and scheduled a November 9 webcast for first JANX011 data.

Janux Therapeutics, Inc. (JANX), a clinical-stage biopharmaceutical company developing immunotherapies on its TRACTr, TRACIr and ARM platforms, dosed the first patient in a Phase 1 study of JANX013 in combination with JANX007 in patients with metastatic castration-resistant prostate cancer, the first clinical evaluation of its TRACIr platform.

The company had said in its second-quarter update that JANX013 remained on track for clinical initiation in the second half of 2026. President and Chief Executive Officer David Campbell said the company continued to execute across its clinical portfolio during the third quarter.

JANX007, the lead PSMA-targeted TRACTr, continued Phase 1b development in mCRPC, with dose optimization and expansion in taxane-naïve patients, including an actively enrolling cohort combining JANX007 with darolutamide. JANX014, a double-masked PSMA-TRACTr, continued enrollment in its Phase 1 study.

JANX011, a CD19-targeted ARM and the company’s first clinical candidate from the ARM platform, remained in a Phase 1 study in healthy volunteers. Janux said initial clinical data from that study would be presented on an investor webcast on November 9, 2026, after the second-quarter release had said the data were expected in the second half of 2026. The company also disclosed that JANX011 selectively engages TRBV6-expressing T cells rather than broadly engaging the CD3+ T cell population, a mechanistic detail not in the prior-quarter update. Additional JANX007 data are expected at a medical congress in the first half of 2027.

Cash, cash equivalents and short-term investments were $945.7 million as of September 30, 2026, down from $970.9 million at June 30, 2026, after a $14.5 million increase in the prior quarter from $956.4 million at March 31, 2026.

Research and development expenses were $30.6 million for the quarter ended September 30, 2026, down from $31.0 million in the quarter ended June 30, 2026, after R&D had risen from $26.8 million in the quarter ended March 31, 2026. General and administrative expenses were $10.0 million. Net loss was $21.6 million, or $0.34 a share, on 63.1 million weighted-average shares.

Collaboration revenue was $9.3 million for the three months ended September 30, 2026, compared with $10.0 million a year earlier. Loss from operations was $31.3 million. Total other income was $9.7 million.

The current portion of deferred revenue was $27.2 million as of September 30, 2026, versus zero at December 31, 2025. Accounts receivable were $0.4 million. Cash and cash equivalents were $41.8 million and short-term investments $903.9 million. Stockholders’ equity was $911.6 million.

Janux said it continues to generate additional TRACTr, TRACIr and ARM programs for potential future development.